On Demand Activities

An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy

0.50 hr(s) | CME , MOC , ABIM

Specialty: Chronic Fibrosing Interstitial Lung Disease

Therapeutic Area(s): Pulmonology

Release Date: May 25, 2021

Expiration Date: May 24, 2022

Location: Internet Activity Enduring

In this activity, an expert in interstitial lung disease discusses the diagnosis of and novel and emerging therapies to treat chronic fibrosing interstitial lung disease.

Finding the Path to Improved Outcomes in Uncontrolled Persistent Asthma: Applying the Latest Clinical Evidence for Treatment Success

0.50 hr(s) | CME

Specialty: Asthma

Therapeutic Area(s): Pulmonology

Release Date: July 28, 2020

Expiration Date: July 27, 2021

Location: Internet Activity Enduring

In this activity, an expert in pulmonology discusses key issues in the diagnosis and treatment of patients with uncontrolled persistent asthma. Several case vignettes provide insights on assessing phenotype/endotype and eligibility for biologic therapy in these patients, in the context of common comorbidities and other patient-, disease-, and treatment-related factors.

Teaming Up to Improve Liver Cancer Outcomes Through Locoregional and Systemic Therapeutic Strategies: A Multidisciplinary Tumor Board Guiding Optimal Care for Patients Along the Intermediate-to-Advanced Disease Continuum

hr(s) | CME

Specialty: Liver Cancer

Therapeutic Area(s): Oncology , Hepatology

Release Date: July 22, 2020

Expiration Date: July 21, 2021

Location: Internet Activity Enduring

Hepatocellular carcinoma (HCC) is a complex liver malignancy for which a variety of treatment modalities, based on disease stage and patient factors, are available. Traditionally, interventional radiologists (IR) have had a key role in managing intermediate-stage disease through the use of locoregional approaches, while oncologists have employed systemic therapy in the realm of advanced-stage disease. However, an improved understanding of HCC pathology has led to the realization that optimal approaches to selecting, combining, sequencing, and transitioning between different modalities has the potential to improve outcomes across disease settings, underscoring the importance of a multidisciplinary team-based approach to HCC management. As approvals for new drugs (eg, TKIs, antiangiogenic agents, immunotherapy, combinations) and positive clinical trial outcomes with novel multimodal strategies continue to impact the HCC treatment paradigm, clinical decision-making has become complicated, with many questions arising about optimal approaches to administering various therapies to the appropriate patient in a timely manner within a team-based care model. In this CME-certified online activity, a multidisciplinary panel of interventional radiology, hepatology, and oncology experts offers insights on how to navigate the intermediate- to advanced-stage HCC landscape in an era of evolving treatment—from use of modern IR approaches to newer systemic therapies and combination strategies—to provide the most benefit for patients with HCC.

Making MS Treatment Decisions Before, During and After Pregnancy: Focus on the Use of Disease-Modifying Therapies

0.50 hr(s) | CME

Specialty: Multiple Sclerosis

Therapeutic Area(s): Neurology

Release Date: January 22, 2021

Expiration Date: January 21, 2022

Location: Internet Activity Enduring

In this activity, an expert on the management of multiple sclerosis (MS) in women discusses current perspectives on the treatment of MS in women of childbearing age, including the appropriate use of disease-modifying therapies (DMTs) before, during, and after pregnancy.

Selective Inhibition of Oncogenic Transcription and Other Novel Approaches in the Treatment of Small Cell Lung Cancer: An Illustrative Guide to Navigating the Evolving Treatment Landscape and Integrating Latest Treatment Modalities Into Clinical Care

0.75 hr(s) | CME

Specialty: SCLC

Therapeutic Area(s): Oncology

Release Date: January 29, 2021

Expiration Date: January 28, 2022

Location: Internet Activity Enduring

In this activity, an expert in small cell lung cancer provides an overview of the features and challenges associated with the condition, as well as the current treatment landscape.

Visualizing Progress for TP53 Mutant AML: A Pathology-Guided Journey through Diagnostic Principles and Modern Treatment

0.50 hr(s) | CME , MOC , ABIM , ABPath , CC

Specialty: AML

Therapeutic Area(s): Oncology

Release Date: May 5, 2021

Expiration Date: May 4, 2022

Location: Internet Activity Enduring

In this activity, an expert pathologist discusses the prognostic relevance of TP53 mutations, current diagnostic tools and principles for capturing TP53-mutated acute myeloid leukemia (AML), and new developments with innovative therapy for TP53-mutated AML.

1 2 3 12
Copy link
Powered by Social Snap